Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonx Corporation SEC filings document the company’s medical technology business, Nasdaq-listed common stock and formal disclosures around operating results, governance, compensation and capital structure. Recent 8-K filings furnish quarterly and annual financial results for the Zephyr Valve-focused lung disease treatment business, including revenue by geography, gross margin, restructuring activity and related management commentary.
The filing record also includes material agreement disclosures for a senior secured term loan facility, proxy materials covering annual meeting proposals, director elections, auditor ratification and executive compensation votes, and 8-K disclosures tied to leadership transitions, separation arrangements and inducement equity awards.
Burns Thomas William reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Thomas William Burns received an equity grant in the form of restricted stock units. The award covers 40,000 shares of Pulmonx common stock at a stated price of $0.0000 per share, reflecting a compensation grant rather than a market purchase.
According to the terms, the restricted stock units vest on the earlier of the one-year anniversary of the June 5, 2026 grant date (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Burns directly holds 113,399 shares of Pulmonx common stock.
Ferrari Richard reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Richard Ferrari reported an equity award. He received 40,000 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per share. These RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date or the next annual stockholders’ meeting. Following this award, Ferrari directly holds 127,024 Pulmonx shares.
Florin Daniel P reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Florin Daniel P reported an award of 40,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 133,910 shares following the transaction.
The RSU grant vests on the earlier of the one-year anniversary of the June 5, 2026 grant date, or the date of the company’s next annual stockholder meeting for the subsequent year, subject to the business day convention described.
Melenikiotou Georgia reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Georgia Melenikiotou reported an equity compensation grant. She was awarded 40,000 shares of common stock as a grant of Restricted Stock Units on June 5, 2026, with no cash paid per share. Following this award, her direct holdings total 139,714 common shares.
The RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date, adjusted to the next business day if needed, or the date of the Annual Meeting of the Stockholders for the year after the grant.
Sullivan Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Tiffany Sullivan received an equity grant in the form of restricted stock units. The Form 4 reports an award of 40,000 shares of common stock at a price of $0.0000 per share, reflecting a compensation-related grant rather than an open-market purchase.
The RSU Grant vests on the earlier of the one-year anniversary of the grant date of June 5, 2026 (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Sullivan directly holds 115,199 common shares.
Mead Dana G Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Dana G. Mead Jr. received a grant of 40,000 Restricted Stock Units payable in common stock. This is a stock-based compensation award, not an open-market purchase.
The RSUs vest on the earlier of June 5, 2026 or the company’s next annual stockholder meeting. After this grant, Mead holds 139,714 Pulmonx common shares directly and 4,076 shares indirectly through The Mead Family Trust.
Pulmonx Corporation reported the results of its 2026 annual meeting of stockholders. A total of 32,645,270 shares were present or represented by proxy, representing approximately 77.29% of the 42,237,203 shares outstanding and entitled to vote as of April 7, 2026.
Stockholders elected three Class III directors — Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr. — to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the company’s executive compensation as described in the proxy statement.
Pulmonx Corp Chief Science & Techn. Officer Radhakrishnan Srikanth reported routine share sales tied to tax withholding. On June 1, 2026, he sold a total of 14,497 shares of Pulmonx common stock in four open-market transactions at $1.54 per share. According to the footnotes, each sale was made solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026.
Pulmonx Corp General Counsel David Aaron Lehman reported the sale of a total of 14,594 shares of Pulmonx common stock on June 1, 2026 at a price of $1.54 per share, executed in four separate transactions. According to the footnotes, all of these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026, making the activity compensation- and tax-related rather than a discretionary reduction of his investment position.
Pulmonx Corp’s Chief Commercial Officer Geoffrey Beran Rose reported multiple small sales of Pulmonx common stock. In total, he sold 8,023 shares at $1.54 per share on June 1, 2026.
According to the footnotes, each sale was made solely to cover tax withholding obligations tied to vesting Restricted Stock Units granted in 2023, 2024, 2025, and 2026. After these transactions, he continues to hold 463,956 Pulmonx shares directly, indicating these are routine tax-related dispositions rather than a broad reduction of his position.